Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24 Week Randomised, Open Label, 3 Parallel-group Comparison of Once and Twice Daily Biphasic Insulin Aspart (BIAsp) 30 Plus Sitagliptin and Twice Daily BIAsp 30, All in Combination With Metformin in Insulin naïve Type 2 Diabetic Subjects Inadequately Controlled on Sitagliptin and Metformin

NCT01519674 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01519674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01519674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24 Week Randomised, Open Label, 3 Parallel-group Comparison of Once and Twice Daily Biphasic Insulin Aspart (BIAsp) 30 Plus Sitagliptin and Twice Daily BIAsp 30, All in Combination With Metformin in Insulin naïve Type 2 Diabetic Subjects Inadequately Controlled on Sitagliptin and Metformin
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2012
Completion date
October 31, 2013
Enrollment
582 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2